The Top 5 Biosimilars Articles for the Week of November 20

The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of November 20.


Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of November 20.

Number 5: The European Medicines Agency will move to Amsterdam, Netherlands, after European ministers voted on the agency’s post-Brexit relocation.

Number 4: A recently published case study shows that a non-medical switch to biosimilar infliximab was associated with a rapid loss of treatment response in multiple patients with Behçet's disease.

Number 3: Samsung Bioepis has been granted the first European marketing authorization for a trastuzumab biosimilar, referenced on Herceptin.

Number 2: Stacie Phan, president of the Biosimilars Forum, explains the critical need for US physicians to gain better education on biosimilar therapies.

Number 1: Swiss drug maker Roche has sued biosimilar developer Pfizer over its proposed trastuzumab biosimilar.

Finally, last week, our e-newsletter asked whether you think that the so-called “nocebo” effect adequately explains patients switching away from biosimilars. To view results of the poll, visit The Center for Biosimilars® on LinkedIn.

To read all of these articles and more, visit

Related Videos
Michael Kleinrock
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Ian Henshaw
John Gabrielson
Ryan Haumschild, PharmD, MS, MBA
Ryan Haumdschild, PharmD
Ryan Haumschild, PharmD
Ryan Haumschild, PharmD
Related Content
© 2023 MJH Life Sciences

All rights reserved.